Panel: Getting your start-up funded, do's and dont's

By BioGeneration Ventures & M Ventures

Bauke Anninga | Investment Director | M Ventures

Bauke Anninga, PhD, joined M Ventures in 2019 and is currently an Investment Director in the Biotechnology team. In this capacity he is a board member of Enara Bio, NanoSyrinx, Nucleome Therapeutics, Outrun Therapeutics, Pictor Labs and Rewind Therapeutics and formerly of Synaffix (until acquisition by Lonza).

Before joining M Ventures, Bauke worked at Jefferies International in the Healthcare Investment Banking group in London (UK). During his time at Jefferies, he advised on several financings and M&A transactions across the biotechnology, pharmaceutical and medical devices sectors. Before that, he was involved in a boutique life-science investment sourcing and due diligence company in Cambridge (UK). He also co-founded the Innovation Forum (UK), which is a global network and accelerator for science-based ventures.

Bauke has a PhD in Cancer Studies from King’s College London (UK) and an MSc in Technical Medicine from the University of Twente (The Netherlands).

About M-Ventures

M Ventures is the strategic, corporate venture capital fund of Merck, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.

We invest - with dual strategic and financial foci - into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence.

We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success.